ABSTRACT
Data from randomized controlled trials suggest that treating hypertension in the elderly, including octogenarians, may substantially reduce the risk of cardiovascular disease and death. However, treatment remains challenging because of comorbidities and aging-related changes. We present common case scenarios encountered while managing elderly patients with hypertension, including secondary hypertension, adverse effects of drugs, labile hypertension, orthostatic hypotension, and dementia.
Footnotes
↵a Dr. Gasowski has disclosed teaching and speaking for the Servier and Zentiva companies.
↵b Dr. Grodzicki has disclosed teaching and speaking for the Servier and Novartis companies.
↵c Dr. Messerli has disclosed consulting for Novartis, Daiichi Sankyo, Pfizer, Takeda, Abbott, PharmApprove, Gilead, Servier, Bayer, and Medtronic and receiving grant support from Forest and Boehringer Ingelheim.
- Copyright © 2012 The Cleveland Clinic Foundation. All Rights Reserved.